Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer
نویسندگان
چکیده
منابع مشابه
Tamoxifen Resistance in Breast Cancer
Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer. The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor. Thi...
متن کاملTRIB2 contributes to cisplatin resistance in small cell lung cancer
Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most important components among all standard poly-chemotherapeutic regimens for SCLC; therefore, this study focused on revealing Cisplatin-resistance mechanism(s) in this disease. Cisplatin-resistant SCLC ce...
متن کاملOxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
Tamoxifen is the accepted therapy for patients with estrogen receptor-α (ERα)-positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes death from metastases. To improve breast cancer treatment it is vital to understand the mechanisms that result in tamoxifen resistance. This study shows that concentratio...
متن کاملUnderstanding resistance to tamoxifen in hormone receptor-positive breast cancer.
The selective estrogen receptor (ER) modulator tamoxifen has been used for more than 30 years to treat and, more recently, to prevent breast cancer. Unfortunately, even among patients with ER-positive tumors, the response achieved with tamoxifen treatment is variable. Recent years have seen a sharp increase in the number of studies suggesting that the efficacy and safety of anticancer therapies...
متن کامل1 Bim degradation contributes to cisplatin resistance
Cisplatin is the first l ine chemotherapy for the treatment of several cancers. However, the development of cisplatin resistance represents a major clinical problem and the mechanisms of acquired resistance are not fully understood. Here we show that degradation of the BH3only pro-apoptotic protein Bim plays an important role in cisplatin resistance in ovarian cancer. Specifically, we show that...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Oncology
سال: 2020
ISSN: 1019-6439,1791-2423
DOI: 10.3892/ijo.2020.4987